Polymeric nanoparticles for cancer therapy

Journal of Drug Targeting

Volumn 16, Issue 2, 2008, Pages 108-123

  Parveen, Suphiya ^a   Sahoo, Sanjeeb K ^a  

^a INSTITUTE OF LIFE SCIENCES   (India)

Author keywords

Biodegradable polymers; Cancer; Drug delivery; Nanoparticles

Indexed keywords

ALPHA TOCOPHEROL; ANTINEOPLASTIC AGENT; APTAMER; CANCER VACCINE; CERAMIDE; CHITOSAN; CISPLATIN; DOCETAXEL; DOXORUBICIN; FOLIC ACID; GADOLINIUM; HUMAN SERUM ALBUMIN; HYPERICIN; IODINATED POPPYSEED OIL; MACROGOL; METHOTREXATE; MITOXANTRONE; NANOPARTICLE; PACLITAXEL; PHOTOSENSITIZING AGENT; POLOXAMER; POLYCAPROLACTONE; POLYGLACTIN; POLYLACTIDE; POLYMER; QUININE; TAMOXIFEN; TRANSFERRIN; TRITIUM; UNINDEXED DRUG;

ANTIGEN ANTIBODY REACTION; ANTINEOPLASTIC ACTIVITY; ANUS CARCINOMA; BINDING AFFINITY; BIOCOMPATIBILITY; BIODEGRADABILITY; BONE MARROW SUPPRESSION; BRAIN MALARIA; BRAIN TUMOR; BREAST CANCER; CANCER RESISTANCE; CANCER THERAPY; CLINICAL TRIAL; CONTROLLED DRUG RELEASE; CYTOTOXICITY; DOSAGE SCHEDULE COMPARISON; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DELIVERY SYSTEM; DRUG DISTRIBUTION; DRUG DOSAGE FORM COMPARISON; DRUG EFFICACY; DRUG FORMULATION; DRUG PENETRATION; DRUG RELEASE; DRUG SPECIFICITY; DRUG STABILITY; DRUG TARGETING; DRUG TUMOR LEVEL; DRUG UPTAKE; ENCAPSULATION; HEAD AND NECK CANCER; HUMAN; HYPERSENSITIVITY REACTION; LUNG NON SMALL CELL CANCER; MAXIMUM TOLERATED DOSE; MELANOMA; MOLECULAR IMAGING; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; NANOTECHNOLOGY; NONHUMAN; OVARY CANCER; PHOTODYNAMIC THERAPY; POLYMERIZATION; PRIORITY JOURNAL; PROSTATE CARCINOMA; PROSTATE TUMOR; REVIEW; SINGLE DRUG DOSE; SOLID TUMOR; SQUAMOUS CELL CARCINOMA; SURVIVAL RATE; TUMOR REGRESSION; TUMOR XENOGRAFT; UTERINE CERVIX CANCER;

ANIMALS; ANTINEOPLASTIC AGENTS; DRUG CARRIERS; DRUG DELIVERY SYSTEMS; DRUG DESIGN; HUMANS; NANOPARTICLES; NEOPLASMS; POLYMERS;

EID: 39449102666     PISSN: 1061186X     EISSN: 10292330     Source Type: Journal    
DOI: 10.1080/10611860701794353     Document Type: Review

References (119)

1. Agnihotri, SA, Mallikarjuna, NN and Aminabhavi, TM (2004) Recent advances on chitosan-based micro- and nanoparticles in drug delivery. J Control Release, 100, pp. 5-28.
2. Akerman, ME, Chan, WC, Laakkonen, P., Bhatia, SN and Ruoslahti, E. (2002) Nanocrystal targeting in vivo. Proc Natl Acad Sci USA, 99, pp. 12617-12621.
3. Arangoa, MA, Duzgunes, N. and de Ilarduya, C Tros (2003) Increased receptor-mediated gene delivery to the liver by protamine-enhanced-asialofetuin-lipoplexes. Gene Ther, 10, pp. 5-14.
4. Astete, CE and Sabliov, CM (2006) Synthesis and characterization of PLGA nanoparticles. J Biomater Sci Polym Ed, 17, pp. 247-289.
5. Au, JL, Jang, SH, Zheng, J., Chen, CT, Song, S., Hu, L. and Wientjes, MG (2001) Determinants of drug delivery and transport to solid tumors. J Control Release, 74, pp. 31-46.
6. Bae, KH, Lee, Y. and Park, TG (2007) Oil-encapsulating PEO-PPO-PEO/PEG shell cross-linked nanocapsules for target-specific delivery of paclitaxel. Biomacromolecules, 8, pp. 650-656.
7. Banerjee, HN and Verma, M. (2006) Use of nanotechnology for the development of novel cancer biomarkers. Expert Rev Mol Diagn, 6, pp. 679-683.
8. Banks, WA and Kastin, AJ (1998) Characterization of lectin-mediated brain uptake of HIV-1 GP120. J Neurosci Res, 54, pp. 522-529.
9. Bies, C., Lehr, CM and Woodley, JF (2004) Lectin-mediated drug targeting: History and applications. Adv Drug Deliv Rev, 56, pp. 425-435.
10. Bodnar, M., Hartmann, JF and Borbely, J. (2005) Preparation and characterization of chitosan-based nanoparticles. Biomacromolecules, 6, pp. 2521-2527.
11. Brannon-Peppas, L. and Blanchette, JO (2004) Nanoparticle and targeted systems for cancer therapy. Adv Drug Deliv Rev, 56, pp. 1649-1659.
12. Burgstaller, P., Jenne, A. and Blind, M. (2002) Aptamers and aptazymes: Accelerating small molecule drug discovery. Curr Opin Drug Discov Devel, 5, pp. 690-700.
13. Chan, WC, Maxwell, DJ, Gao, X., Bailey, RE, Han, M. and Nie, S. (2002) Luminescent quantum dots for multiplexed biological detection and imaging. Curr Opin Biotechnol, 13, pp. 40-46.
14. Cho, YW, Park, SA, Han, TH, Son, DH, Park, JS, Oh, SJ, Moon, DH, Cho, KJ, Ahn, CH, Byun, Y., Kim, IS, Kwon, IC and Kim, SY (2007) In vivo tumor targeting and radionuclide imaging with self-assembled nanoparticles: Mechanisms, key factors, and their implications. Biomaterials, 28, pp. 1236-1247.
15. Damascelli, B., Cantu, G., Mattavelli, F., Tamplenizza, P., Bidoli, P., Leo, E., Dosio, F., Cerrotta, AM, Tolla, G Di, Frigerio, LF, Garbagnati, F., Lanocita, R., Marchiano, A., Patelli, G., Spreafico, C., Ticha, V., Vespro, V. and Zunino, F. (2001) Intraarterial chemotherapy with polyoxyethylated castor oil free paclitaxel, incorporated in albumin nanoparticles (ABI-007): Phase II study of patients with squamous cell carcinoma of the head and neck and anal canal: Preliminary evidence of clinical activity. Cancer, 92, pp. 2592-2602.
16. Daniels, TR, Delgado, T., Helguera, G. and Penichet, ML (2006) The transferrin receptor part II: Targeted delivery of therapeutic agents into cancer cells. Clin Immunol, 121, pp. 159-176.
17. Daniels, TR, Delgado, T., Rodriguez, JA, Helguera, G. and Penichet, ML (2006) The transferrin receptor part I: Biology and targeting with cytotoxic antibodies for the treatment of cancer. Clin Immunol, 121, pp. 144-158.
18. De Mejia, EG and Prisecaru, VI (2005) Lectins as bioactive plant proteins: A potential in cancer treatment. Crit Rev Food Sci Nutr, 45, pp. 425-445.
19. Dellian, M., Witwer, BP, Salehi, HA, Yuan, F. and Jain, RK (1996) Quantitation and physiological characterization of angiogenic vessels in mice: Effect of basic fibroblast growth factor, vascular endothelial growth factor/vascular permeability factor, and host microenvironment. Am J Pathol, 149, pp. 59-71.
20. Devalapally, H., Duan, Z., Seiden, MV and Amiji, MM (2007) Paclitaxel and ceramide co-administration in biodegradable polymeric nanoparticulate delivery system to overcome drug resistance in ovarian cancer. Int J Cancer, 121, pp. 1830-1880.
21. Dodane, V. and Vivivalam, VD (1998) Pharmaceutical applications of chitosan. Pharm Sci Technol Today, 1, pp. 246-253.
22. Dreis, S., Rothweiler, F., Michaelis, M., Cinatl Jr., J., Kreuter, J. and Langer, K. (2007) Preparation, characterisation and maintenance of drug efficacy of doxorubicin-loaded human serum albumin (HSA) nanoparticles. Int J Pharm, 341, pp. 207-214.
23. Drolet, DW, Nelson, J., Tucker, CE, Zack, PM, Nixon, K., Bolin, R., Judkins, MB, Farmer, JA, Wolf, JL, Gill, SC and Bendele, RA (2000) Pharmacokinetics and safety of an anti-vascular endothelial growth factor aptamer (NX1838) following injection into the vitreous humor of rhesus monkeys. Pharm Res, 17, pp. 1503-1510.
24. Ellington, AD and Szostak, JW (1990) In vitro selection of RNA molecules that bind specific ligands. Nature, 346, pp. 818-822.
25. Emerich, DF and Thanos, CG (2003) Nanotechnology and medicine. Expert Opin Biol Ther, 3, pp. 655-663.
26. Faisant, N., Siepmann, J. and Benoit, JP (2002) PLGA-based microparticles: Elucidation of mechanisms and a new, simple mathematical model quantifying drug release. Eur J Pharm Sci, 15, pp. 355-366.
27. Fang, J., Sawa, T. and Maeda, H. (2003) Factors and mechanism of "EPR" effect and the enhanced anti-tumor effects of macromolecular drugs including SMANCS. Adv Exp Med Biol, 519, pp. 29-49.
28. Farokhzad, OC, Cheng, J., Teply, BA, Sherifi, I., Jon, S., Kantoff, PW, Richie, JP and Langer, R. (2006) Targeted nanoparticle-aptamer bioconjugates for cancer chemotherapy in vivo. Proc Natl Acad Sci USA, 103, pp. 6315-6320.
29. Farokhzad, OC, Karp, JM and Langer, R. (2006) Nanoparticle-aptamer bioconjugates for cancer targeting. Expert Opin Drug Deliv, 3, pp. 311-324.
30. Feng, SS (2004) Nanoparticles of biodegradable polymers for new-concept chemotherapy. Expert Rev Med Devices, 1, pp. 115-125.
31. Feng, SS and Chien, S. (2003) Chemotherapeutic engineering: Application and further development of chemical engineering principles for chemotherapy of cancer and other diseases. Chem Engr Sci, 58, pp. 4087-4114.
32. Fischer, D. and Kissel, T. (2001) Histochemical characterization of primary capillary endothelial cells from porcine brains using monoclonal antibodies and fluorescein isothiocyanate-labelled lectins: Implications for drug delivery. Eur J Pharm Biopharm, 52, pp. 1-11.
33. Fonsatti, E., Altomonte, M., Arslan, P. and Maio, M. (2003) Endoglin (CD105): A target for anti-angiogenetic cancer therapy. Curr Drug Targets, 4, pp. 291-296.
34. Fontana, G., Maniscalco, L., Schillaci, D., Cavallaro, G. and Giammona, G. (2005) Solid lipid nanoparticles containing tamoxifen characterization and in vitro antitumoral activity. Drug Deliv, 12, pp. 385-392.
35. Gao, X., Cui, Y., Levenson, RM, Chung, LW and Nie, S. (2004) In vivo cancer targeting and imaging with semiconductor quantum dots. Nat Biotechnol, 22, pp. 969-976.
36. Greish, K., Fang, J., Inutsuka, T., Nagamitsu, A. and Maeda, H. (2003) Macromolecular therapeutics: Advantages and prospects with special emphasis on solid tumour targeting. Clin Pharmacokinet, 42, pp. 1089-1105.
37. Grodzinski, P., Silver, M. and Molnar, LK (2006) Nanotechnology for cancer diagnostics: Promises and challenges. Expert Rev Mol Diagn, 6, pp. 307-318.
38. Gryparis, EC, Hatziapostolou, M., Papadimitriou, E. and Avgoustakis, K. (2007) Anticancer activity of cisplatin-loaded PLGA-mPEG nanoparticles on LNCaP prostate cancer cells. Eur J Pharm Biopharm, 67, pp. 1-8.
39. Gupta, Y., Jain, A. and Jain, SK (2005) Transferrin-conjugated solid lipid nanoparticles for enhanced delivery of quinine dihydrochloride to the brain. J Am Chem Soc, 127, pp. 11364-11371.
40. Hicke, BJ and Stephens, AW (2000) Escort aptamers: A delivery service for diagnosis and therapy. J Clin Invest, 106, pp. 923-928.
41. Hilgenbrink, AR and Low, PS (2005) Folate receptor-mediated drug targeting: From therapeutics to diagnostics. J Pharm Sci, 94, pp. 2135-2146.
42. Hoshino, A., Hanaki, K., Suzuki, K. and Yamamoto, K. (2004) Applications of T-lymphoma labeled with fluorescent quantum dots to cell tracing markers in mouse body. Biochem Biophys Res Commun, 314, pp. 46-53.
43. Hsi, RA, Rosenthal, DI and Glatstein, E. (1999) Photodynamic therapy in the treatment of cancer: Current state of the art. Drugs, 57, pp. 725-734.
44. Park, J Hyung, Kwon, S., Lee, M., Chung, H., Kim, JH, Kim, YS, Park, RW, Kim, IS, Seo, S Bong, Kwon, IC and Jeong, S Young (2006) Self-assembled nanoparticles based on glycol chitosan bearing hydrophobic moieties as carriers for doxorubicin: In vivo biodistribution and anti-tumor activity. Biomaterials, 27, pp. 119-126.
45. Ibrahim, NK, Desai, N., Legha, S., Soon-Shiong, P., Theriault, RL, Rivera, E., Esmaeli, B., Ring, SE, Bedikian, A., Hortobagyi, GN and Ellerhorst, JA (2002) Phase I and pharmacokinetic study of ABI-007, a Cremophor-free, protein-stabilized, nanoparticle formulation of paclitaxel. Clin Cancer Res, 8, pp. 1038-1044.
46. Illum, L. (1998) Chitosan and its use as a pharmaceutical excipient. Pharm Res, 15, pp. 1326-1331.
47. Jain, RA (2000) The manufacturing techniques of various drug loaded biodegradable poly(lactide-co-glycolide) (PLGA) devices. Biomaterials, 21, pp. 2475-2490.
48. Jeong, YI, Seo, SJ, Park, IK, Lee, HC, Kang, IC, Akaike, T. and Cho, CS (2005) Cellular recognition of paclitaxel-loaded polymeric nanoparticles composed of poly(gamma-benzyl -glutamate) and poly(ethylene glycol) diblock copolymer endcapped with galactose moiety. Int J Pharm, 296, pp. 151-161.
49. Kim, JH, Kim, YS, Kim, S., Park, JH, Kim, K., Choi, K., Chung, H., Jeong, SY, Park, RW, Kim, IS and Kwon, IC (2006) Hydrophobically modified glycol chitosan nanoparticles as carriers for paclitaxel. J Control Release, 111, pp. 228-234.
50. Kirpotin, DB, Drummond, DC, Shao, Y., Shalaby, MR, Hong, K., Nielsen, UB, Marks, JD, Benz, CC and Park, JW (2006) Antibody targeting of long-circulating lipidic nanoparticles does not increase tumor localization but does increase internalization in animal models. Cancer Res, 66, pp. 6732-6740.
51. Koziara, JM, Lockman, PR, Allen, DD and Mumper, RJ (2004) Paclitaxel nanoparticles for the potential treatment of brain tumors. J Control Release, 99, pp. 259-269.
52. Kukowska-Latallo, JF, Candido, KA, Cao, Z., Nigavekar, SS, Majoros, IJ, Thomas, TP, Balogh, LP, Khan, MK and Baker, JRJ (2005) Nanoparticle targeting of anticancer drug improves therapeutic response in animal model of human epithelial cancer. Cancer Res, 65, pp. 5317-5324.
53. Kumagai, M., Imai, Y., Nakamura, T., Yamasaki, Y., Sekino, M., Ueno, S., Hanaoka, K., Kikuchi, K., Nagano, T., Kaneko, E., Shimokado, K. and Kataoka, K. (2007) Iron hydroxide nanoparticles coated with poly(ethylene glycol)-poly(aspartic acid) block copolymer as novel magnetic resonance contrast agents for in vivo cancer imaging. Colloids Surf B Biointerfaces, 56, pp. 174-181.
54. Labhasetwar, V. (1997) Nanoparticles for drug delivery. Pharm News, 4, pp. 28-31.
55. Labhasetwar, V., Song, C. and Levy, RJ (1997) Nanoparticle drug delivery for restinosis. Adv Drug Del Rev, 24, pp. 63-85.
56. Lamprecht, A., Ubrich, N., Yamamoto, H., Schafer, U., Takeuchi, H., Maincent, P., Kawashima, Y. and Lehr, CM (2001) Biodegradable nanoparticles for targeted drug delivery in treatment of inflammatory bowel disease. J Pharmacol Exp Ther, 299, pp. 775-781.
57. Lee, S. and Perez-Luna, VH (2005) Dextran-gold nanoparticle hybrid material for biomolecule immobilization and detection. Anal Chem, 77, pp. 7204-7211.
58. Lee, MK, Lim, SJ and Kim, CK (2007) Preparation, characterization and in vitro cytotoxicity of paclitaxel-loaded sterically stabilized solid lipid nanoparticles. Biomaterials, 28, pp. 2137-2146.
59. Lian, W., Litherland, SA, Badrane, H., Tan, W., Wu, D., Baker, HV, Gulig, PA, Lim, DV and Jin, S. (2004) Ultrasensitive detection of biomolecules with fluorescent dye-doped nanoparticles. Anal Biochem, 334, pp. 135-144.
60. Lin, R., Ng, L Shi and Wang, CH (2005) In vitro study of anticancer drug doxorubicin in PLGA-based microparticles. Biomaterials, 26, pp. 4476-4485.
61. Liu, SQ, Wiradharma, N., Gao, SJ, Tong, YW and Yang, YY (2007) Bio-functional micelles self-assembled from a folate-conjugated block copolymer for targeted intracellular delivery of anticancer drugs. Biomaterials, 28, pp. 1423-1433.
62. Lu, Y. and Low, PS (2002) Folate-mediated delivery of macromolecular anticancer therapeutic agents. Adv Drug Deliv Rev, 54, pp. 675-693.
63. Luo, Y. and Prestwich, GD (2002) Cancer-targeted polymeric drugs. Curr Cancer Drug Targets, 2, pp. 209-226.
64. Maeda, H., Wu, J., Sawa, T., Matsumura, Y. and Hori, K. (2000) Tumor vascular permeability and the EPR effect in macromolecular therapeutics: A review. J Control Release, 65, pp. 271-284.
65. Matsumura, Y. and Maeda, H. (1986) A new concept for macromolecular therapeutics in cancer chemotherapy: Mechanism of tumoritropic accumulation of proteins and the antitumor agent SMANCS. Cancer Res, 46, pp. 6387-6392.
66. McCaughan Jr, JS (1999) Photodynamic therapy: A review. Drugs Aging, 15, pp. 49-68.
67. Michalet, X., Pinaud, FF, Bentolila, LA, Tsay, JM, Doose, S., Li, JJ, Sundaresan, G., Wu, AM, Gambhir, SS and Weiss, S. (2005) Quantum dots for live cells, in vivo imaging, and diagnostics. Science, 307, pp. 538-544.
68. Mo, Y. and Lim, LY (2005) Preparation and in vitro anticancer activity of WGA-conjugated PLGA nanoparticles loaded with paclitaxel and isopropyl myristate. J Control Release, 107, pp. 30-42.
69. Moghimi, SM, Hunter, AC and Murray, JC (2001) Long-circulating and target-specific nanoparticles: Theory to practice. Pharmacol Rev, 53, pp. 283-318.
70. Nie, S., Xing, Y., Kim, GJ and Simons, JW (2007) Nanotechnology applications in cancer. Annu Rev Biomed Eng, 9, pp. 257-288.
71. Oyewumi, MO, Yokel, RA, Jay, M., Coakley, T. and Mumper, RJ (2004) Comparison of cell uptake, biodistribution and tumor retention of folate-coated and PEG-coated gadolinium nanoparticles in tumor-bearing mice. J Control Release, 95, pp. 613-626.
72. Palumbo, G. (2007) Photodynamic therapy and cancer: A brief sightseeing tour. Expert Opin Drug Deliv, 4, pp. 131-148.
73. Panyam, J. and Labhasetwar, V. (2003) Biodegradable nanoparticles for drug and gene delivery to cells and tissue. Adv Drug Deliv Rev, 55, pp. 329-347.
74. Park, TG (1995) Degradation of poly(lactic-co-glycolic acid) microspheres: Effect of copolymer composition. Biomaterials, 16, pp. 1123-1130.
75. Parveen, S. and Sahoo, SK (2006) Nanomedicine: Clinical applications of polyethylene glycol conjugated proteins and drugs. Clin Pharmacokinet, 45, pp. 965-988.
76. Peng, W., Anderson, DG, Bao, Y., Padera Jr., RF, Langer, R. and Sawicki, JA (2007) Nanoparticulate delivery of suicide DNA to murine prostate and prostate tumors. Prostate, 67, pp. 855-862.
77. Pestourie, C., Tavitian, B. and Duconge, F. (2005) Aptamers against extracellular targets for in vivo applications. Biochimie, 87, pp. 921-930.
78. Polakovic, M., Gorner, T., Gref, R. and Dellacherie, E. (1999) Lidocaine loaded biodegradable nanospheres. II Modelling of drug release. J Control Release, 60, pp. 169-177.
79. Qi, LF, Xu, ZR, Li, Y., Jiang, X. and Han, XY (2005) In vitro effects of chitosan nanoparticles on proliferation of human gastric carcinoma cell line MGC803 cells. World J Gastroenterol, 11, pp. 5136-5141.
80. Qi, L., Xu, Z. and Chen, M. (2007) In vitro and in vivo suppression of hepatocellular carcinoma growth by chitosan nanoparticles. Eur J Cancer, 43, pp. 184-193.
81. Ricci-Junior, E. and Marchetti, JM (2006) Preparation, characterization, photocytotoxicity assay of PLGA nanoparticles containing zinc (II) phthalocyanine for photodynamic therapy use. J Microencapsul, 23, pp. 523-538.
82. Sahoo, SK (2005) Applications of nanomedicine. Asia Pacific Biotech News, 9, pp. 1048-1050.
83. Sahoo, SK and Labhasetwar, V. (2003) Nanotech approaches to drug delivery and imaging. Drug Discov Today, 8, pp. 1112-1120.
84. Sahoo, SK and Labhasetwar, V. (2005) Enhanced antiproliferative activity of transferrin-conjugated paclitaxel-loaded nanoparticles is mediated via sustained intracellular drug retention. Mol Pharm, 2, pp. 373-383.
85. Sahoo, SK, Ma, W. and Labhasetwar, V. (2004) Efficacy of transferrin-conjugated paclitaxel-loaded nanoparticles in a murine model of prostate cancer. Int J Cancer, 112, pp. 335-340.
86. Sahoo, SK, Parveen, S. and Panda, JJ (2007) The present and future of nanotechnology in human health care. Nanomedicine, 3, pp. 20-31.
87. Scherer, F., Anton, M., Schillinger, U., Henke, J., Bergemann, C., Kruger, A., Gansbacher, B. and Plank, C. (2002) Magnetofection: Enhancing and targeting gene delivery by magnetic force in vitro and in vivo. Gene Ther, 9, pp. 102-109.
88. Serpe, L., Guido, M., Canaparo, R., Muntoni, E., Cavalli, R., Panzanelli, P., Della Pepal, C., Bargoni, A., Mauro, A., Gasco, MR, Eandi, M. and Zara, GP (2006) Intracellular accumulation and cytotoxicity of doxorubicin with different pharmaceutical formulations in human cancer cell lines. J Nanosci Nanotechnol, 6, pp. 3062-3069.
89. Sharon, N. (2007) Lectins: Carbohydrate-specific reagents and biological recognition molecules. J Biol Chem, 282, pp. 2753-2764.
90. Shenoy, DB and Amiji, MM (2005) Poly(ethylene oxide)-modified poly(epsilon-caprolactone) nanoparticles for targeted delivery of tamoxifen in breast cancer. Int J Pharm, 293, pp. 261-270.
91. Shive, MS and Anderson, JM (1997) Biodegradation and biocompatibility of PLA and PLGA microspheres. Adv Drug Deliv Rev, 28, pp. 5-24.
92. Shi, X., Wang, S., Meshinchi, S., Van Antwerp, ME, Bi, X., Lee, I. and Baker Jr, JR (2007) Dendrimer-entrapped gold nanoparticles as a platform for cancer-cell targeting and imaging. Small, 7, pp. 1245-1252.
93. Sibata, CH, Colussi, VC, Oleinick, NL and Kinsella, TJ (2001) Photodynamic therapy in oncology. Expert Opin Pharmacother, 2, pp. 917-927.
94. Sinha, R., Kim, GJ, Nie, S. and Shin, DM (2006) Nanotechnology in cancer therapeutics: Bioconjugated nanoparticles for drug delivery. Mol Cancer Ther, 5, pp. 1909-1917.
95. Solbrig, CM, Saucier-Sawyer, JK, Cody, V., Saltzman, WM and Hanlon, DJ (2007) Polymer nanoparticles for immunotherapy from encapsulated tumor-associated antigens and whole tumor cells. Mol Pharm, 4, pp. 47-57.
96. Steiniger, SC, Kreuter, J., Khalansky, AS, Skidan, IN, Bobruskin, AI, Smirnova, ZS, Severin, SE, Uhl, R., Kock, M., Geiger, KD and Gelperina, SE (2004) Chemotherapy of glioblastoma in rats using doxorubicin-loaded nanoparticles. Int J Cancer, 109, pp. 759-767.
97. Stinchcombe, TE, Socinski, MA, Walko, CM, O'Neil, BH, Collichio, FA, Ivanova, A., Mu, H., Hawkins, MJ, Goldberg, RM, Lindley, C. and Dees, E Claire (2007) Phase I and pharmacokinetic trial of carboplatin and albumin-bound paclitaxel, ABI-007 (abraxane(R)) on three treatment schedules in patients with solid tumors. Cancer Chemother Pharmacol, 60, pp. 759-766.
98. Thorpe, PE (2004) Vascular targeting agents as cancer therapeutics. Clin Cancer Res, 10, pp. 415-427.
99. Tiyaboonchai, W. (2003) Chitosan nanoparticles: A promising system for drug delivery. Naesuan Univ J, 11, pp. 51-66.
100. Torchilin, VP (2005) Recent advances with liposomes as pharmaceutical carriers. Nat Rev Drug Discov, 4, pp. 145-160.
101. Tsutsui, Y., Tomizawa, K., Nagita, M., Michiue, H., Nishiki, T., Ohmori, I., Seno, M. and Matsui, H. (2007) Development of bionanocapsules targeting brain tumors. J Control Release, 122, pp. 159-164.
102. Tuerk, C. and Gold, L. (1990) Systematic evolution of ligands by exponential enrichment: RNA ligands to bacteriophage T4 DNA polymerase. Science, 249, pp. 505-510.
103. Vasir, JK and Labhasetwar, V. (2005) Targeted drug delivery in cancer therapy. Technol Cancer Res Treat, 4, pp. 363-374.
104. Wang, N., Wu, XS, Li, C. and Feng, MF (2000) Synthesis, characterization, biodegradation, and drug delivery application of biodegradable lactic/glycolic acid polymers: I. Synthesis and characterization. J Biomater Sci Polym Ed, 11, pp. 301-318.
105. Wang, HZ, Wang, HY, Liang, RQ and Ruan, KC (2004) Detection of tumor marker CA125 in ovarian carcinoma using quantum dots. Acta Biochim Biophys Sin (Shanghai), 36, pp. 681-686.
106. Wang, MD, Shin, DM, Simons, JW and Nie, S. (2007) Nanotechnology for targeted cancer therapy. Expert Rev Anticancer Ther, 7, pp. 833-837.
107. Weiner, LM (2006) Fully human therapeutic monoclonal antibodies. J Immunother, 29, pp. 1-9.
108. White, RR, Sullenger, BA and Rusconi, CP (2000) Developing aptamers into therapeutics. J Clin Invest, 106, pp. 929-934.
109. Wissing, SA, Kayser, O. and Muller, RH (2004) Solid lipid nanoparticles for parenteral drug delivery. Adv Drug Deliv Rev, 56, pp. 1257-1272.
110. Wong, HL, Bendayan, R., Rauth, AM, Li, Y. and Wu, XY (2007) Chemotherapy with anticancer drugs encapsulated in solid lipid nanoparticles. Adv Drug Deliv Rev, 59, pp. 491-504.
111. Wong, HL, Rauth, AM, Bendayan, R. and Wu, XY (2007) In vivo evaluation of a new polymer-lipid hybrid nanoparticle (PLN) formulation of doxorubicin in a murine solid tumor model. Eur J Pharm Biopharm, 65, pp. 300-308.
112. Xu, Y. and Du, Y. (2003) Effect of molecular structure of chitosan on protein delivery properties of chitosan nanoparticles. Int J Pharm, 250, pp. 215-226.
113. Xu, Z., Gu, W., Huang, J., Sui, H., Zhou, Z., Yang, Y., Yan, Z. and Li, Y. (2005) In vitro and in vivo evaluation of actively targetable nanoparticles for paclitaxel delivery. Int J Pharm, 288, pp. 361-368.
114. Yemisci, M., Bozdag, S., Cetin, M., Soylemezoglu, F., Capan, Y., Dalkara, T. and Vural, I. (2006) Treatment of malignant gliomas with mitoxantrone-loaded poly (lactide-co-glycolide) microspheres. Neurosurgery, 59, pp. 1296-1302.
115. Yoo, HS and Park, TG (2004) Folate receptor targeted biodegradable polymeric doxorubicin micelles. J Control Release, 96, pp. 273-283.
116. Zeisser-Labouebe, M., Lange, N., Gurny, R. and Delie, F. (2006) Hypericin-loaded nanoparticles for the photodynamic treatment of ovarian cancer. Int J Pharm, 326, pp. 174-181.
117. Zhang, Z. and Feng, SS (2006) The drug encapsulation efficiency, in vitro drug release, cellular uptake and cytotoxicity of paclitaxel-loaded poly(lactide)-tocopheryl polyethylene glycol succinate nanoparticles. Biomaterials, 27, pp. 4025-4033.
118. Zhang, Z., Huey, LS and Feng, SS (2007) Folate-decorated poly(lactide-co-glycolide)-vitamin E TPGS NPs for targeted drug delivery. Biomaterials, 28, pp. 1889-1899.
119. Muhlen, A zur, Schwarz, C. and Mehnert, W. (1998) Solid lipid nanoparticles (SLN) for controlled drug delivery-drug release and release mechanism. Eur J Pharm Biopharm, 45, pp. 149-155.